As CT cannabis industry grows, new office is created to regulate it

April 9, 2025

The Department of Consumer Protection is removing oversight and enforcement of the marijuana industry from the agency’s Drug Control Division less than a month after state officials apologized for what appeared to be a retaliatory inspection at a cannabis cultivation facility.

The licensing, regulatory and inspection functions for the industry will be shifted to a separate division within the Department of Consumer Protection, the agency announced on Wednesday. Lila McKinley, a DCP attorney who has been involved in developing the regulations for Connecticut’s adult-use cannabis market, will lead that new arm of the agency.

The regulatory shift was being developed before state officials were forced to apologize for the inspection incident at cultivation facility in Portland, but its implementation was accelerated as a result, a department spokesperson said.

DCP officials sent an email to all of the licensed cannabis operators in the state Wednesday morning informing them of the creation of the new regulatory office, which oversee both medical and recreation marijuana.

“For nearly a year, we have contemplated organizational changes that would allow for more specialized attention to your complex and growing industry,” the message to license holders said. “This change reflects your evolving industry as we are restructuring to better meet your regulatory needs.”

Bryan Cafferelli, the commissioner of consumer protection, said the way the state previously regulated the cannabis industry made sense when dispensaries were limited to selling medical marijuana. But he said the oversight functions needed to change now that Connecticut companies are selling tens of millions of dollars in recreational weed every month.

“Restructuring the Drug Control Division has been in the works for nearly a year, as we contemplated the best way to meet the growing needs and complexities of the cannabis industry while ensuring continued success in our regulation of the pharmaceutical industry in Connecticut,” Cafferelli said in a statement.

“Our agency is adapting to meet the needs of both industries and protect public health and safety,” he added.

 

Search

RECENT PRESS RELEASES